A Splendid New Beginning at the End of a 40-Year Quest: The First KRASG12D Inhibitor in Pancreatic Cancer

Redding, Alexandra; Grabocka, Elda

doi:10.1158/2159-8290.CD-22-1304

Article navigation

In the Spotlight| February 06 2023

A Splendid New Beginning at the End of a 40-Year Quest: The First KRAS^G12D Inhibitor in Pancreatic Cancer

Alexandra Redding

0000-0002-2834-1398

;

Alexandra Redding

Department of Pharmacology, Physiology, and Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.

Search for other works by this author on:

This Site

PubMed

Google Scholar

Elda Grabocka

0000-0001-7196-8498

Elda Grabocka *

Department of Pharmacology, Physiology, and Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.

*Corresponding Author: Elda Grabocka, Department of Pharmacology, Physiology, and Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, 233 South 10th Street, BLSB 1002, Philadelphia, PA 19107. Phone: 215-503-7783; E-mail: exg002@jefferson.edu

Search for other works by this author on:

This Site

PubMed

Google Scholar

Author & Article Information

*Corresponding Author: Elda Grabocka, Department of Pharmacology, Physiology, and Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, 233 South 10th Street, BLSB 1002, Philadelphia, PA 19107. Phone: 215-503-7783; E-mail: exg002@jefferson.edu

Cancer Discov 2023;13:260–2

Online ISSN: 2159-8290

Print ISSN: 2159-8274

Funding

Funding Group:

Award Group:
- Funder(s):
  National Cancer Institute (NCI)
- Award Id(s):
  T32CA236736
Award Group:
- Funder(s):
  National Cancer Institute (NCI)
- Award Id(s):
  R37CA160495

2023

American Association for Cancer Research

Cancer Discov (2023) 13 (2): 260–262.

https://doi.org/10.1158/2159-8290.CD-22-1304

Summary:

The first KRAS^G12D inhibitor, MRTX113, leads to regression in multiple mouse models of PDAC as a monotherapy. MRTX113 blocks cancer cell proliferation, induces cancer cell death, and promotes immune infiltration and activation.

2023

American Association for Cancer Research

You do not currently have access to this content.

Don't already have an account? Register

You could not be signed in. Please check your email address / username and password and try again.

A Splendid New Beginning at the End of a 40-Year Quest: The First KRAS^G12D Inhibitor in Pancreatic Cancer

Citing articles via

Email alerts

AACR Journals

A Splendid New Beginning at the End of a 40-Year Quest: The First KRASG12D Inhibitor in Pancreatic Cancer

Sign in

Client Account

Citing articles via

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only

A Splendid New Beginning at the End of a 40-Year Quest: The First KRAS^G12D Inhibitor in Pancreatic Cancer